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Abstract Serum amyloid A (SAA) is a major acute-phase
protein whose biochemical functions remain largely obscure.
Human rheumatic synovial fluids were screened by high
performance liquid chromatography mass spectrometry for
SAA-derived peptides, specifically the sequence AGLPEKY
(SAA98ÿ104) which was previously shown to modulate various
leukocyte functions. Two such fluids were found to contain a
truncated version of SAA98ÿ104. Synthetic SAA98ÿ104 and several
of its analogs were shown capable of binding isolated human
CD+4 T-lymphocytes and stimulating them to produce interferon-
Q. Given the high acute-phase serum level of SAA and its massive
proteolysis by inflammatory related enzymes, SAA-derived
peptides may be involved in host defense mechanisms.
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1. Introduction
Human serum amyloid A (SAA) is a major acute-phase
protein (APP), whose blood concentration may soar dramat-
ically, as high as 1000-fold above the normal level during
in£ammatory events. However, the precise biochemical and
immunological roles of this APP have not been fully estab-
lished. SAA, a single chain 104 amino acid protein, exists in
the body in complex with the third fraction of high density
lipoprotein, and is primarily synthesized by hepatocytes [1].
As in£ammation subsides, SAA is quickly cleared from the
plasma and very low basal levels are re-established [2^4].
Although the catabolic pathway of SAA has not been com-
pletely de¢ned, studies with isolated human neutrophils and
monocytes provided evidence for SAA degradation by cell-
associated elastase-like proteases [5^8]. Several other serine
proteases found in serum, including kallikrein and plasmin,
also have been shown to degrade SAA [9,10]. However, the
particular sites cleaved by the various proteases were not iden-
ti¢ed in these studies. Recently, the e¡ects of neutrophil elas-
tase and cathepsin B on SAA degradation were examined [11].
Both enzymes degraded SAA at the carboxy-terminus and
generated fragments comprised of the ¢rst 58 or 76 residues
of SAA.
In previous studies, we have demonstrated that SAA is
proteolysed by the lysosomal enzymes of human neutrophils
to generate peptides which may be intimately involved in the
acute-phase response [12]. Markedly enhanced levels of SAA
and neutrophils are found in various in£ammatory diseases in
which synovial £uid accumulates within joints [13]. Therefore,
we screened human in£ammatory synovial £uids for speci¢c
SAA-derived peptides, previously shown in our laboratory to
induce interferon-Q (IFNQ) secretion by human T-lymphocytes
(Oren Rosen, 1995, Ph.D. thesis, Weizmann Institute of Sci-
ence, unpublished data).
2. Materials and methods
Unless otherwise stated, all chemicals and reagents were obtained
from Sigma Chemicals (St. Louis, MO, USA). Phosphate-bu¡ered
saline (PBS), HEPES, DMEM medium and RPMI 1640 medium
were obtained from the Biological Services of the Weizmann Institute
of Science. Tissue culture reagents were purchased from Beit-Haemek
Biological Industries. Human recombinant SAA (rSAA) was kindly
donated by Peprotec Ltd. (Ness-Ziona, Israel). Human recombinant
IFNQ was purchased from Cytolab Ltd. (Ness-Ziona, Israel). Re-
combinant human SAA was puri¢ed from bacterial phospholipids
as previously described [14]. From 1 g of crude SAA, 28 mg of
pure SAA was obtained.
2.1. Synovial £uid processing
Synovial £uids (approximately 50 ml each) were collected following
knee perfusions, centrifuged for 15 min at 3000 rpm and stored at
320‡C. The cell free solutions were thawed and diluted with three
volumes of ethanol and allowed to stand overnight at 4‡C. The white
precipitates, composed primarily of proteoglycans, were then centri-
fuged for 15 min at 5000 rpm (4‡C), the supernatants were evaporated
to a minimum volume, suspended in 10% trichloroacetic acid (TCA)
and allowed to stand overnight at 4‡C to pellet the high molecular
weight proteins. The solutions were centrifuged for 15 min at 8000
rpm (4‡C) and the supernatants extracted with three volumes of cold
ether. The processed £uids were then puri¢ed by high performance
liquid chromatography (HPLC) (Spectra-Physics SP-8800) using a
prepacked Lichrospher-100 RP-18 column (4U25 mm, 5 Wm bead
size) employing a binary gradient formed from 0.1% tri£uoroacetic
acid (TFA) in water (solution A) and 0.1% TFA in acetonitrile (so-
lution B). The typical elution gradient used was: t = 0 min B = 5%,
t = 5 min B = 5%, t = 65 min B = 70% (£ow rate 0.8 ml/min). Solvents
and columns were obtained from Merck (Darmstadt, Germany).
2.2. Mass spectrometry (MS)
Electrospray (ES) mass spectra were recorded on an API-III triple
quadrupole mass spectrometer (Perkin Elmer Sciex, Thornhill, Ont.,
Canada) equipped with an ES source using atmospheric pressure ion-
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ization. For MS detection, the positive ion mode was used and the
ori¢ce voltage was set to 80 V. For multiple reaction monitoring
(MRM) using MS/MS mode, argon was used as a collision gas. For
HPLC-MS analysis, samples were chromatographically separated on
Nucleosil C-18 2U100 column (Grom, Herrenberg, Germany) using
an Applied Biosystems 140A HPLC (Weiterstadt, Germany) con-
nected to the ES source. A linear gradient 10% B to 100% B in
45 min was used (solvent A: 0.1% TFA in water; solvent B: 0.1%
TFA in acetonitrile).
2.3. Peptide synthesis
Peptides were prepared by Fmoc strategy of solid phase peptide
synthesis using an Abimed AMS-422 peptide synthesizer, puri¢ed to
above 98% by preparative HPLC, and analyzed using an HP-1090
amino acid analyzer as previously described [15]. Without exception,
amino acid analysis of all peptides yielded excellent correspondence to
calculated ratios ( þ 10%).
2.4. Iodination of SAA98ÿ104
SAA98ÿ104 was labeled with 125I by employing the chloramine T
procedure. Na125I (Amersham, UK; 1 mCi, speci¢c activity 644
MBq/Wg iodine) was added to a solution of SAA98ÿ104 (10 Wg) and
chloramine T (1.5 Wg) in 0.5 M sodium phosphate bu¡er, pH = 7.5
(11.5 Wl). The iodination reaction was stopped after 3 min at room
temperature (RT) by addition of sodium metabisul¢te (3.5 Wg) in
sodium phosphate bu¡er (35 Wl). Free radioactive iodine was sepa-
rated from the labeled protein by adding a solution of KI (20%; 10 Wl)
followed by loading the reaction mixture on a Sephadex G10 column
(0.5U15 cm; Pharmacia, Sweden). The column was eluted with cal-
cium and magnesium free PBS containing 0.1% bovine serum albumin
(BSA). The speci¢c activity was 1.5 WCi/Wg SAA98ÿ104.
2.5. Peripheral human CD+4 T-lymphocytes
Human CD4 T-cells were puri¢ed from the peripheral blood leu-
kocytes of healthy donors as previously described [14]. Over 90% of
the resulting cells were CD4 T-lymphocytes, as determined by FACS-
can analysis.
2.6. IFNQ secretion and detection
T-cells were suspended in RPMI medium (RPMI 1640 supple-
mented with 2% BSA, 1 mM Ca2, 1 mM Mg2, 1% sodium pyru-
vate, 1% glucose and 1% HEPES bu¡er) and seeded in 24-well plates
(Nunc, Denmark) (1.5U106 cells/well). The cells were incubated with
SAA-derived peptides at various concentrations (1^500 WM) for 18 h,
37‡C, in a humidi¢ed 10% CO2 atmosphere. As a positive control of
IFNQ secretion, phytohemoagglutinin (PHA) stimulation at a concen-
tration of 1 Wg/ml was used. Subsequently, the media contents in wells
were collected and centrifuged, and the supernatants were assayed for
the cytokine protein level using two-sites sandwich enzyme-linked im-
munosorbent assay: ¢rst antibody attachment to the 96 microtiter
wells (Nunc, Denmark) was performed by incubating (18 h, 4‡C)
puri¢ed rat anti-human IFNQ monoclonal antibody (Pharmingen,
CA, USA) (2 Wg/ml) in a ¢nal volume of 50 Wl/well. The coating bu¡er
contained 0.1 N NaHCO3, pH 8.2. The plates were then washed twice
with 0.05% Tween 20/PBS and blocked with 3% BSA/PBS solution for
1 h at RT. Following extensive washes, supernatants obtained from
incubation of T-cells with SAA and SAA peptides were added to the
wells (100 Wl/well) and left for 2 h at RT. For calibration of secre-
tion, a double-diluted series of recombinant IFNQ was used. Follow-
ing incubation and washing, biotinylated anti-IFNQ (2 Wg/ml,
100 Wl/well) was added and left for 2 h at RT. Alkaline phospha-
tase-conjugated streptavidin (Jackson Immunoresearch Laboratories,
PA, USA) (1:1000 dilution, 100 Wl/well) was added for 30 min at RT.
Following extensive washing and substrate addition (PNPP), the ab-
sorbance was measured at 405 nm with a microplate reader (Dyna-
tech, CA, USA).
2.7. Binding and displacement experiments
For binding assays, two series having identical concentrations of
125I-SAA98ÿ104 in PBS containing 0.1% BSA were prepared by sequen-
tial double dilutions. One, designed for evaluation of non-speci¢c
binding, contained 10^0.1 WM SAA98ÿ104 and 100^1 nM 125I-
SAA98ÿ104, respectively. The other designed for the total binding
curve contained only 100^1 nM 125I-SAA98ÿ104. Human T-cells ad-
hered to polystyrene surfaces (96-well microtiter plates; 2U105 cells/
100 Wl/well) were incubated at 4‡C for 40 min with appropriate li-
gands. Following incubation, reaction was stopped by aspirating un-
bound ligands followed by several washes (three times) with ice cold
PBS. Cells were lysed with 0.1 N NaOH solution (150 Wl/well) con-
taining 1% Tween 20, the mixture was then transferred to Q-counter
tubes and radioactivity was measured (Kontron MD-480). In dis-
placement experiments with 125I-SAA98ÿ104, a concentrated series of
either unlabeled SAA98ÿ104 or other competing ligands (peptides re-
lated to SAA98ÿ104) were prepared in binding mixture (i.e. 40 nM
125I-SAA98ÿ104, 0.1% BSA in PBS). The initial concentration of cold
ligands was 10 WM and by sequential double dilutions reached a
concentration of 10 nM. Incubation with cells and lysis were per-
formed as described above.
3. Results and discussion
The carboxy-terminal sequence of SAA (AGLPEKY,
SAA98ÿ104) was found in a synovial £uid of an arthritic pa-
tient. Preliminary results have demonstrated that the peptide
stimulates IFNQ production by mononuclear cells as well as
inhibiting superoxide production and chemotaxis of activated
neutrophils (Oren Rosen, Ph.D. thesis, Weizmann Institute;
unpublished data).
To establish the physiological existence of peptides related
to SAA98ÿ104, eight additional synovial £uids were processed.
These £uids were obtained from patients a¥icted with rheu-
matoid arthritis and processed by ethanol/TCA precipitation
(see Section 2). The peptide-containing lyophilized fractions
were puri¢ed by reversed phase HPLC. Optimal chromato-
graphic conditions were achieved by injecting 25% of each
sample (approximately 10^20 mg dry weight containing 0.5^
1 mg peptide) on an analytical column and resulted in com-
plex chromatograms containing a large number of unidenti-
¢ed peaks (not shown). Peptide content was estimated by
amino acid analysis of combined eluted peaks.
Fractions were collected 3 min prior and after the elution
time of the synthetic peptide AGLPEKY98ÿ104 chromato-
graphed under identical conditions (i.e. 26^32 min). From
the eight synovial £uids evaluated, ¢ve samples which con-
tained signi¢cant UV absorbing peaks in the elution region
of 26^32 min were characterized by HPLC-MS. The SAA-
derived peptide A98GLPEK103 (614 amu) was unambiguously
identi¢ed by ES-MS in two di¡erent synovial £uids (Table 1).
Synthetic AGLPEK peptide was also prepared and shown to
match the retention times and molecular weight values ob-
tained from the physiological samples. In a further experi-
ment, MRM was performed which considers only ion inten-
sities from characteristic fragments, directed towards
increasing sensitivity. The characteristic fragment 373.2 amu
assigned to AGLP in the MRM run was found in both syno-
vial £uids and in the synthetic peptide. A98GLPEK103 di¡ers
from A98GLPEKY104 by a single C-terminus tyrosine residue.
Table 1
Mass spectrometric data of HPLC-puri¢ed fractions from two dif-
ferent synovial £uids
Sample Observed m/z Sequence Calculated mass
Fluid # 5 614.1 (M+H) AGLPEK 614.3 (M+H)
636.3 (M+Na) AGLPEK 636.3 (M+Na)
485.1 fragment: AGLPE 485.5
485.1 fragment: LPEK 485.5
Fluid # 8 614.2 (M+H) AGLPEK 614.3 (M+H)
286.8 fragment: GLP 286.3
228.6 fragment: LP 228.8
Ionization conditions for the two samples are not identical, resulting
in di¡erent fragmentation patterns.
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Cleavage of SAA by a trypsin-like enzyme may perhaps ac-
count for formation of a shorter sequence since Arg97 and
Lys103 precede the Ala98 and Tyr104 residues, respectively.
In order to study bio-activity and structure^function rela-
tionships of SAA98ÿ104 and several analogs, they were synthe-
sized, puri¢ed, analyzed and evaluated for their ability to
modulate the IFNQ secretory activity of human CD4 T-lym-
phocytes, at concentrations comparable with the acute-phase
levels of intact SAA (Table 2). SAA-derived peptide 1 (AGL-
PEKY), similar to the intact rSAA, increased substantially the
secretion of IFNQ by human T-lymphocytes. From the various
synthetic peptide analogs tested (peptides 2^15), peptide
length seems to be crucial for its biological activity. Eliminat-
ing C- or N-terminus residues of peptide 1 (peptides 2^5)
abolished the IFNQ secretory activity. Systematic single ala-
nine substitutions of residues 100^104 (peptides 6^10) demon-
strates the functional importance of the amino acids P101-E-
K-Y104. In contrast, the Leu100 residue may be replaced by
alanine without e¡ecting substantially the IFNQ secretory ac-
tivity (peptide 10). Noteworthy, the aromatic ring of Tyr104
may be substituted by phenylalanine without loss of stimula-
tory activity (peptide 11). In a similar fashion, the positive
charge at the Lys103 residue and the negative charge at the
Glu102 residue may be replaced by similarly charged Arg and
Asp residues, respectively, with only a 2-fold reduction in
activity (peptides 12^13). When Pro101 was replaced by sarco-
sine (a non-bridged analog of proline), the enhancing capa-
bility was almost totally abolished (peptide 14), stressing the
unique structural importance of proline in this peptide. The
retro-peptide (peptide 15), used as control compound, proved
to have no in£uence on T-cell IFNQ secretion.
Peptide 1 and its active peptide analogs were found capable
of modulating IFNQ secretion levels by T-cell in a dose-depen-
dent manner (Fig. 1). As a rule, higher activities were appar-
ent at peptide concentrations of 100^500 WM.
SAA was previously shown to associate avidly with speci¢c
extra-cellular matrix (ECM) moieties [14]. Upon complexation
Table 2
IFNQ secretion activity of human T-lymphocytes, stimulated by
SAA-derived peptides, analogs, rSAA and PHA (positive control),
measured 20 min following substrate addition (see Section 2)
Substance Sequence Concentration IFNQ secretion
(OD units
405 nm)
rSAA 104 amino acids 100 WM 2.0 þ 0.2
Medium ^ ^ 0.2 þ 0.1
PHA+medium ^ 1 mg/ml 1.9 þ 0.2
Peptide 1 AGLPEKY 100 WM 1.5 þ 0.2
Peptide 2 AGLPEK 100 WM 0.3 þ 0.1
Peptide 3 AGLPE 100 WM 0.2 þ 0.1
Peptide 4 GLPEKY 100 WM 0.2 þ 0.1
Peptide 5 LPEKY 100 WM 0.2 þ 0.1
Peptide 6 AGLPEKA 100 WM 0.3 þ 0.1
Peptide 7 AGLPEAY 100 WM 0.2 þ 0.1
Peptide 8 AGLPAKY 100 WM 0.6 þ 0.1
Peptide 9 AGLAEKY 100 WM 0.2 þ 0.1
Peptide 10 AGAPEKY 100 WM 1.1 þ 0.2
Peptide 11 AGLPEKF 100 WM 1.5 þ 0.2
Peptide 12 AGLPERY 100 WM 0.9 þ 0.2
Peptide 13 AGLPDKY 100 WM 0.8 þ 0.2
Peptide 14 AGL-Sar-EKY 100 WM 0.2 þ 0.1
Peptide 15 YKEPLGA 100 WM 0.2 þ 0.1
Experiments were performed using leukocytes obtained from three
di¡erent blood donations. Bold letters denote amino acid substitu-
tion. Sar is sarcosine (n-methyl-glycine). Peptide 15 is the reverse se-
quence of SAA98ÿ104.
Fig. 1. IFNQ secretion by human T-lymphocytes: a dose-dependent
e¡ect. Results are mean values from three experiments with S.D.
values below 10%. Medium control, PHA values and experimental
conditions are identical to those described in Table 2.
Fig. 2. Speci¢c binding of 125I-SAA98ÿ104 to human T-lymphocytes.
The mean values from two experiments are shown (S.D. values are
below 10%). Insert: Scatchard analysis of the 125I-SAA98ÿ104 binding
to human T-lymphocytes. Considering a homogeneous population
of binding sites, a dissociation constant of 12 nM was found.
Fig. 3. Inhibition of 125I-SAA98ÿ104 binding to human T-lympho-
cytes by peptide analogs of SAA98ÿ104. The retro-peptide (peptide
15 was used as a negative control). Results are mean values from
two experiments (S.D. values are below 10%).
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with SAA, immobilized ECM, laminin and vitronectin in-
duced markedly the adhesion of human CD4 T-cells in a
L1-integrin-mediated manner. Another study described the
binding characteristics of SAA to human neutrophils [12].
Speci¢cally, the C-terminus fragment SAA77ÿ104 was shown
to inhibit the binding of intact SAA to neutrophils.
To study the mechanism of activity, SAA98ÿ104 (peptide 1)
was tested for its ability to bind speci¢cally to human T-lym-
phocytes. The binding of peptide 1 was saturable and speci¢c
(Fig. 2). The plotted data provided curves which were ex-
pressed as Scatchard plots upon transforming experimental
bound and free values according to the Langmuir binding
model. The dissociation constant (Kd) determined was 12
nM, considering an averaged homogeneous population (Fig.
2, insert). Non-speci¢c binding, i.e. the fraction of 125I-
SAA98ÿ104 detected in the presence of 100-fold excess of un-
labeled SAA98ÿ104, represented 18 þ 5% (S.D.) of the total cell-
associated radioactivity in the absence of competing ligand.
Competition assays were also performed with synthetic pep-
tides related to SAA98ÿ104. Only peptide 11 completely inhib-
ited the binding of 125I-SAA98ÿ104 to human T-lymphocytes.
Partial inhibition (50%) was obtained with peptide 12 (Fig. 3).
These results correlate well with the stimulatory values deter-
mined for peptides 12 and 13 and with the lack of activity
observed in peptide 15.
The issue of the physiological function(s) of SAA is largely
unresolved. In view of our present and previous ¢ndings
[12,14], it is most plausible that SAA, either intact or through
its proteolytic fragments, is associated with immune cell func-
tion and activation. The levels of SAA in various pathological
conditions, such as acute in£ammation, may reach concentra-
tions of 1^2 mg/ml (V100^200 WM). Considering the fast
proteolysis of SAA by di¡erent enzymes, most notably those
derived from polymorphonuclear leukocytes, levels of related
peptide derivatives may reach similar values. Moreover, local
concentrations of SAA-derived peptides may even be much
higher at in£icted tissues where leukocytes and SAA co-accu-
mulate and speci¢cally associate with each other. At these
levels, SAA-derived peptides (such as SAA98ÿ104) may possess
a substantial in vivo modulatory e¡ect on the T-cell secretion
of IFNQ and thus be directly involved in host defense immune
response.
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